Mesalazine Market Revenue 2024 to 2034
Mesalazine Market Revenue 2024 to 2034
The Mesalazine Market is projected to grow from USD 12.93 Bn in 2024 to USD 56.26 Bn by 2034, at a CAGR of 15.8%. Growth is fueled by the rising prevalence of inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn’s disease, advancements in oral and rectal formulations, and expanding access to effective anti-inflammatory therapies worldwide.
Report ID: 10388
|
Format: Databook
|
Published: August 2025
|
Delivery: Immediate
Download Sample
Customisation Request
Revenue,
USD 12.93 Bn
Forecast Year,
USD 56.26 Bn
CAGR, 2025 -
15.84%
Report Coverage
Worldwide
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
Mesalazine Market Size Analysis
Mesalazine Market Size By Product & Service 2024 to 2034 (USD )
| Product & Service | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | 5.95 | 6.89 | 7.93 | 9.15 | 10.65 | 12.31 | 14.17 | 16.38 | 19.03 | 21.96 | 25.46 |
| Services | 4.65 | 5.39 | 6.29 | 7.29 | 8.39 | 9.74 | 11.40 | 13.22 | 15.21 | 17.72 | 20.60 |
| Software | 2.33 | 2.69 | 3.12 | 3.65 | 4.23 | 4.91 | 5.67 | 6.58 | 7.68 | 8.88 | 10.20 |
Mesalazine Market Size By Application 2024 to 2034 (USD )
| Application | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical | 4.65 | 5.39 | 6.23 | 7.22 | 8.38 | 9.65 | 11.21 | 13.01 | 15.11 | 17.47 | 20.27 |
| Research | 3.62 | 4.19 | 4.84 | 5.61 | 6.48 | 7.56 | 8.70 | 10.03 | 11.65 | 13.58 | 15.68 |
| Operations | 3.10 | 3.61 | 4.21 | 4.88 | 5.67 | 6.55 | 7.61 | 8.81 | 10.18 | 11.72 | 13.64 |
| Others | 1.55 | 1.78 | 2.06 | 2.38 | 2.75 | 3.20 | 3.72 | 4.34 | 4.97 | 5.79 | 6.66 |
Mesalazine Market Size By End-User 2024 to 2034 (USD )
| End-User | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals/Providers | 5.43 | 6.25 | 7.21 | 8.32 | 9.62 | 11.16 | 12.88 | 14.94 | 17.29 | 20.02 | 23.23 |
| Pharma & Biotech | 3.36 | 3.92 | 4.56 | 5.28 | 6.14 | 7.10 | 8.29 | 9.54 | 11.02 | 12.77 | 14.79 |
| Payers/Govt | 1.55 | 1.81 | 2.09 | 2.44 | 2.83 | 3.29 | 3.81 | 4.39 | 5.12 | 5.89 | 6.84 |
| Academic/Research | 2.07 | 2.40 | 2.78 | 3.24 | 3.75 | 4.33 | 5.01 | 5.87 | 6.83 | 7.96 | 9.17 |
| Others | 0.52 | 0.60 | 0.70 | 0.81 | 0.93 | 1.08 | 1.25 | 1.45 | 1.66 | 1.92 | 2.23 |
Mesalazine Market Size By Region 2024 to 2034 (USD )
| Region | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 4.91 | 5.70 | 6.59 | 7.65 | 8.85 | 10.30 | 11.89 | 13.77 | 15.97 | 18.54 | 21.35 |
| Europe | 3.62 | 4.19 | 4.90 | 5.66 | 6.56 | 7.56 | 8.77 | 10.20 | 11.82 | 13.66 | 15.87 |
| Asia Pacific | 3.36 | 3.88 | 4.46 | 5.17 | 5.99 | 6.94 | 8.05 | 9.31 | 10.76 | 12.47 | 14.51 |
| Latin America | 0.52 | 0.60 | 0.70 | 0.81 | 0.94 | 1.09 | 1.26 | 1.45 | 1.68 | 1.94 | 2.24 |
| Middle East & Africa | 0.52 | 0.60 | 0.70 | 0.81 | 0.94 | 1.08 | 1.26 | 1.46 | 1.69 | 1.95 | 2.30 |
Proceed To Buy
Proceed To CheckoutMake Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Quick Contact
- NA : +1 804 441 9344
- APAC : +91 9356 9282 04
- EU : +44 7782 560 738
- sales@precedenceresearch.com
